June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Validation of a Photographic Retinopathy of Prematurity Severity Score (ROP–SS) and Comparison to the Modified Activity Score (mROP–ActS) in a Retrospective SUNDROP Cohort
Author Affiliations & Notes
  • Christine Liu Xu
    Stanford University School of Medicine, Stanford, California, United States
  • Joel Adu-Brimpong
    Stanford University School of Medicine, Stanford, California, United States
  • Henry P. Moshfeghi
    Carleton College, Northfield, Minnesota, United States
  • Tatiana R. Rosenblatt
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Michael Yu
    Stanford University School of Medicine, Stanford, California, United States
  • Sean Wang
    Stanford University School of Medicine, Stanford, California, United States
  • Moosa Zaidi
    Stanford University School of Medicine, Stanford, California, United States
  • Hashem Ghoraba
    Stanford University School of Medicine, Stanford, California, United States
  • Suzanne Michalak
    Stanford University School of Medicine, Stanford, California, United States
  • Natalia F. Callaway
    Stanford University School of Medicine, Stanford, California, United States
  • Edward H. Wood
    Austin Retina Associates, Austin, Texas, United States
  • Andreas Stahl
    Universitat Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
  • Domenico Lepore
    Universita Cattolica del Sacro Cuore, Milano, Lombardia, Italy
  • Darius M Moshfeghi
    Stanford University School of Medicine, Stanford, California, United States
  • Footnotes
    Commercial Relationships   Christine Xu None; Joel Adu-Brimpong None; Henry Moshfeghi None; Tatiana Rosenblatt None; Michael Yu None; Sean Wang None; Moosa Zaidi None; Hashem Ghoraba None; Suzanne Michalak None; Natalia Callaway Genentech, Code C (Consultant/Contractor), Genentech, Code E (Employment), Genentech, Code S (non-remunerative); Edward Wood None; Andreas Stahl Alcon, Code C (Consultant/Contractor), Bayer, Novartis, Roche, Code R (Recipient); Domenico Lepore None; Darius Moshfeghi Affamed, Ainsly Limited, Alexion, Plenoptika Inc., Prime Medical Education, SLACK Inc., Vindico, Code C (Consultant/Contractor), Ainsly Limited, dSentz Inc., Plenoptika Inc., Pr3vent inc, Promisight Inc, Pykus, Visunex Medical Systems Co. Ltd, Code E (Employment), dSentz Inc., Code F (Financial Support)
  • Footnotes
    Support  RESEARCH TO PREVENT BLINDNESS, INC., NEI P30-EY026877
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3346. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christine Liu Xu, Joel Adu-Brimpong, Henry P. Moshfeghi, Tatiana R. Rosenblatt, Michael Yu, Sean Wang, Moosa Zaidi, Hashem Ghoraba, Suzanne Michalak, Natalia F. Callaway, Edward H. Wood, Andreas Stahl, Domenico Lepore, Darius M Moshfeghi; Validation of a Photographic Retinopathy of Prematurity Severity Score (ROP–SS) and Comparison to the Modified Activity Score (mROP–ActS) in a Retrospective SUNDROP Cohort. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3346.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Telemedicine for identification and treatment of retinopathy of prematurity (ROP) is becoming ubiquitous, necessitating a grading system to gauge ROP disease severity. The modified ROP Activity Scale (mROP-ActS) addresses the totality of binocular burden via indirect ophthalmoscopy. There is the unmet need for an alternative score, which would be used to facilitate ROP identification and to gauge the level of disease improvement or deterioration specifically on photographic telemedicine exams. Here, we propose a Photographic ROP scoring system (ROP Severity Score [ROP-SS]) which we have validated and compared against the modified mROP-ActS system.

Methods : The SUNDROP database includes data from 12 NICUs over ≥17 years beginning in 2005.We abstracted data from SUNDROP, anonymized and de-identified it and placed into a secure HIPAA-compliant online storage folder.

We assessed the features of ROP that resulted in a treatment intervention and then created an ROP-SS ranging from 0-100, with disproportionate weighting for Zone I, Plus, and Stage 3 (Table 1). We also introduced severity levels, such as "treatment-warranted" which scores from 55-85.

Each eye per visit was scored for both ROP-SS and mROP-ActS. We conducted descriptive analysi and simple arithmetic was applied to determine how often the ROP-SS and mROP-ActS returned a score for the SUNDROP dataset for the following outcomes: 1) overall, 2) treated eyes.

Results : The ROP-SS was able to return a score more often than mROP-ActS. Specifically, the ROP-SS returned a score 99.1% of the time, while the mROP-ActS returned a score 80.8% of the time.

ROP-SS outperformed mROP-ActS in predicting subsequent need for treatment. For TW-ROP, overall, there were 39 treatment cases. Of these cases, the ROP-SS identified correctly 38 of the 39 cases (97.4% accuracy); the mROP-ActS identified correctly 26 of the 39 cases (66.7% accuracy) (Table 2).

Conclusions : Photographic telemedicine is important for ROP screening. Here, we demonstrate the rationale for a photographic ROP Severity Scale, and we propose a scoring system with weighted elements that predict treatment interventions and adverse outcomes. We compare ROP-SS to the mROP-ActS and overall, the ROP-SS returned data at a higher percentage and was more accurate in predicting subsequent treatment as compared to the mROP-ActS.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×